FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2999635443> ?p ?o ?g. }

• W2999635443 abstract "Abstract Background Despite increased atherothrombotic risk in type 2 diabetes mellitus, (T2DM) the best preventative antithrombotic strategy remains undetermined. We defined the effects of three antiplatelet agents on functional readout and biomarker kinetics in platelet activation and coagulation in patients with T2DM. Materials and methods 56 patients with T2DM were randomised to antiplatelet monotherapy with aspirin 75 mg once daily (OD), clopidogrel 75 mg OD or prasugrel 10 mg OD during three periods of a crossover study. Platelet aggregation (PA) was determined by light-transmittance aggregometry and P-selectin expression by flow cytometry. Markers of fibrin clot dynamics, inflammation and coagulation were measured. Plasma levels of 14 miRNA were assessed by quantitative polymerase chain reactions. Results Of the 56 patients, 24 (43%) were receiving aspirin for primary prevention of ischaemic events and 32 (57%) for secondary prevention. Prasugrel was the strongest inhibitor of ADP-induced PA (mean ± SD maximum response to 20μmol/L ADP 77.6 ± 8.4% [aspirin] vs. 57.7 ± 17.6% [clopidogrel] vs. 34.1 ± 14.1% [prasugrel], p < 0.001), P-selectin expression (30 μmol/L ADP; 45.1 ± 21.4% vs. 27.1 ± 19.0% vs. 14.1 ± 14.9%, p < 0.001) and collagen-induced PA (2 μg/mL; 62.1 ± 19.4% vs. 72.3 ± 18.2% vs. 60.2 ± 18.5%, p < 0.001). Fibrin clot dynamics and levels of coagulation and inflammatory proteins were similar. Lower levels of miR-24 (p = 0.004), miR-191 (p = 0.019), miR-197 (p = 0.009) and miR-223 (p = 0.014) were demonstrated during prasugrel-therapy vs. aspirin. Circulating miR-197 was lower in those cardiovascular disease during therapy with aspirin (p = 0.039) or prasugrel (p = 0.0083). Conclusions Prasugrel monotherapy in T2DM provided potent platelet inhibition and reduced levels of a number of platelet-associated miRNAs. miR-197 is a potential marker of cardiovascular disease in this population. Clinical outcome studies investigating prasugrel monotherapy are warranted in individuals with T2DM. Trial registration EudraCT, 2009-011907-22. Registered 15 March 2010, https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-011907-22/GB ." @default.
• W2999635443 created "2020-01-23" @default.
• W2999635443 creator A5000289928 @default.
• W2999635443 creator A5012684500 @default.
• W2999635443 creator A5016093410 @default.
• W2999635443 creator A5035588730 @default.
• W2999635443 creator A5036249431 @default.
• W2999635443 creator A5039450208 @default.
• W2999635443 creator A5077961943 @default.
• W2999635443 creator A5081639011 @default.
• W2999635443 creator A5086223086 @default.
• W2999635443 date "2020-01-07" @default.
• W2999635443 modified "2023-10-01" @default.
• W2999635443 title "Aspirin, clopidogrel and prasugrel monotherapy in patients with type 2 diabetes mellitus: a double-blind randomised controlled trial of the effects on thrombotic markers and microRNA levels" @default.
• W2999635443 cites W1553345686 @default.
• W2999635443 cites W179729331 @default.
• W2999635443 cites W1915082808 @default.
• W2999635443 cites W1969497394 @default.
• W2999635443 cites W1972399546 @default.
• W2999635443 cites W1980888291 @default.
• W2999635443 cites W1985835171 @default.
• W2999635443 cites W2007957848 @default.
• W2999635443 cites W2015175766 @default.
• W2999635443 cites W2034942998 @default.
• W2999635443 cites W2036378379 @default.
• W2999635443 cites W2050820265 @default.
• W2999635443 cites W2067925813 @default.
• W2999635443 cites W2091401363 @default.
• W2999635443 cites W2099022345 @default.
• W2999635443 cites W2100012557 @default.
• W2999635443 cites W2103714496 @default.
• W2999635443 cites W2104599604 @default.
• W2999635443 cites W2107277218 @default.
• W2999635443 cites W2112760185 @default.
• W2999635443 cites W2120101441 @default.
• W2999635443 cites W2127604161 @default.
• W2999635443 cites W2138058610 @default.
• W2999635443 cites W2147675498 @default.
• W2999635443 cites W2157454492 @default.
• W2999635443 cites W2161068194 @default.
• W2999635443 cites W2161844490 @default.
• W2999635443 cites W2164386459 @default.
• W2999635443 cites W2165387925 @default.
• W2999635443 cites W2166650056 @default.
• W2999635443 cites W2169387542 @default.
• W2999635443 cites W2173222155 @default.
• W2999635443 cites W2180664789 @default.
• W2999635443 cites W2182042869 @default.
• W2999635443 cites W2193219814 @default.
• W2999635443 cites W2200847231 @default.
• W2999635443 cites W2268109476 @default.
• W2999635443 cites W2298958687 @default.
• W2999635443 cites W2344977044 @default.
• W2999635443 cites W2592424182 @default.
• W2999635443 cites W2729656752 @default.
• W2999635443 cites W2770367451 @default.
• W2999635443 cites W2809601936 @default.
• W2999635443 cites W2899755710 @default.
• W2999635443 cites W2925027084 @default.
• W2999635443 cites W2948401465 @default.
• W2999635443 cites W2953295149 @default.
• W2999635443 cites W2971887322 @default.
• W2999635443 cites W311320695 @default.
• W2999635443 cites W4213222556 @default.
• W2999635443 doi "https://doi.org/10.1186/s12933-019-0981-3" @default.
• W2999635443 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6945631" @default.
• W2999635443 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31910903" @default.
• W2999635443 hasPublicationYear "2020" @default.
• W2999635443 type Work @default.
• W2999635443 sameAs 2999635443 @default.
• W2999635443 citedByCount "28" @default.
• W2999635443 countsByYear W29996354432020 @default.
• W2999635443 countsByYear W29996354432021 @default.
• W2999635443 countsByYear W29996354432022 @default.
• W2999635443 countsByYear W29996354432023 @default.
• W2999635443 crossrefType "journal-article" @default.
• W2999635443 hasAuthorship W2999635443A5000289928 @default.
• W2999635443 hasAuthorship W2999635443A5012684500 @default.
• W2999635443 hasAuthorship W2999635443A5016093410 @default.
• W2999635443 hasAuthorship W2999635443A5035588730 @default.
• W2999635443 hasAuthorship W2999635443A5036249431 @default.
• W2999635443 hasAuthorship W2999635443A5039450208 @default.
• W2999635443 hasAuthorship W2999635443A5077961943 @default.
• W2999635443 hasAuthorship W2999635443A5081639011 @default.
• W2999635443 hasAuthorship W2999635443A5086223086 @default.
• W2999635443 hasBestOaLocation W29996354431 @default.
• W2999635443 hasConcept C126322002 @default.
• W2999635443 hasConcept C134018914 @default.
• W2999635443 hasConcept C2777015399 @default.
• W2999635443 hasConcept C2777028646 @default.
• W2999635443 hasConcept C2777628954 @default.
• W2999635443 hasConcept C2777849778 @default.
• W2999635443 hasConcept C2910068830 @default.
• W2999635443 hasConcept C3018697912 @default.
• W2999635443 hasConcept C555293320 @default.
• W2999635443 hasConcept C71924100 @default.
• W2999635443 hasConcept C89560881 @default.
• W2999635443 hasConcept C90924648 @default.
• W2999635443 hasConcept C98274493 @default.
• W2999635443 hasConceptScore W2999635443C126322002 @default.

• next